Natus Medical (Nasdaq:NTUS) announced today that ArchiMed’s investment firm completed its previously announced acquisition of the company.
In April, the company announced that the MED Platform II fund of ArchiMed — an investment firm focused on the healthcare industry — would acquire Natus, a developer of medical devices for screening, diagnosing and treating disorders affecting the brain, neural pathways, and eight sensory nervous systems, for a total equity value of $1.2 billion.
Under the terms of the acquisition, Natus shareholders received $33.50 in cash for each share of common stock, according to a news release.
“ArchiMed’s mix of operational, medical, scientific and financial expertise will help us continue our mission to serve our customers as we internationalize and grow our business,” Natus CEO Thomas J. Sullivan said in the release. “Our Natus teammates are excited to advance the standard of care and improve outcomes and quality o…